Drug intelligence / Profile preview

FAP-PID

Development stage: Unknown
Lead developer: Kyoto University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

FAP-PID: sourced facts only. name: "FAP-binding affinities of [natIn]-In-FAP-PID and [natIn]-In-FAP-ID were comparable to or higher than those of the monomeric counterparts." [PMID:42312172]; target: "FAP-binding affinities of [natIn]-In-FAP-PID and [natIn]-In-FAP-ID were comparable to or higher than those of the monomeric counterparts." [PMID:42312172]; developer: "Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida, Shimoadachi-cho, Sakyo-Ku, Kyoto 606-8501, Japan." [PMID:42312172]; modality: "In this study, we newly designed and synthesized three types of FAP-targeting dimers based on FAPI-46 and FAP-2286: heterodimer FAP-PID, small molecule-based homodimer FAP-ID, and cyclic peptide-based homodimer FAP-PD." [PMID:42312172]

Beyond the preview

Go deeper on FAP-PID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAP-PID.